FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899693214> ?p ?o ?g. }

• W2899693214 endingPage "71" @default.
• W2899693214 startingPage "64" @default.
• W2899693214 abstract "A hemorragia subaracnoidea por aneurisma é uma importante causa de morte prematura e de incapacidade em todo o mundo. O sulfato de magnésio mostra um efeito neuroprotetor e reverte o vasoespasmo cerebral. A milrinona também é usada no tratamento de vasoespasmo cerebral. O objetivo do presente estudo foi comparar o efeito profilático do sulfato de magnésio e da milrinona sobre a incidência de vasoespasmo cerebral após hemorragia subaracnoidea. O estudo incluiu 90 pacientes com hemorragia subaracnoidea por aneurisma randomicamente distribuídos (randomização simples) em dois grupos: sulfato de magnésio foi administrado em infusão de 500 mg.dia−1 sem dose de ataque durante 21 dias. O Grupo B recebeu milrinona em infusão de 0,5 μg.kg−1·min−1 sem dose de ataque durante 21 dias. O vasoespasmo cerebral foi diagnosticado pela velocidade média do fluxo sanguíneo cerebral na artéria cerebral envolvida (velocidade média do fluxo ≥ 120 cm.s−1), a deterioração neurológica por escala de coma de Glasgow ou angiografia (diminuição do diâmetro da artéria cerebral envolvida > 25%). A velocidade média do fluxo sanguíneo cerebral diminuiu significativamente no grupo magnésio em comparação com o grupo milrinona nos dias 7, 14 e 21 (p < 0,001). A incidência de vasoespasmo cerebral diminuiu significativamente com o magnésio em comparação com milrinona (p = 0,007). A escala de coma de Glasgow melhorou significativamente no grupo magnésio em comparação com o grupo milrinona nos dias 7, 14 e 21 (p = 0,036, p = 0,012, p = 0,016, respectivamente). A incidência de hipotensão foi maior com milrinona do que com magnésio (p = 0,012). A incidência de vasoespasmo cerebral após hemorragia subaracnoidea por aneurisma foi significativamente menor e a escala de coma de Glasgow significativamente melhor com magnésio em comparação com milrinona. A milrinona foi associada a uma maior incidência de hipotensão e necessidade de dopamina e norepinefrina em comparação com o magnésio. Aneurysmal subarachnoid hemorrhage is an important cause of premature death and disability worldwide. Magnesium sulphate is shown to have a neuroprotective effect and it reverses cerebral vasospasm. Milrinone is also used in the treatment of cerebral vasospasm. The aim of the present study was to compare the effect of prophylactic magnesium sulphate and milrinone on the incidence of cerebral vasospasm after subarachnoid hemorrhage. The study included 90 patients with aneurysmal subarachnoid hemorrhage classified randomly (by simple randomization) into two groups: magnesium sulphate was given as an infusion of 500 mg.day−1 without loading dose for 21 days. Group B: milrinone was given as an infusion of 0.5 μg.kg−1.min−1 without loading dose for 21 days. The cerebral vasospasm was diagnosed by mean cerebral blood flow velocity in the involved cerebral artery (mean flow velocity ≥ 120 cm.s−1), neurological deterioration by Glasgow coma scale, or angiography (the decrease in diameter of the involved cerebral artery >25%). The mean cerebral blood flow velocity decreased significantly in the magnesium group compared to milrinone group through Day 7, Day 14 and Day 21 (p < 0.001). The incidence of cerebral vasospasm decreased significantly with magnesium compared to milrinone (p = 0.007). The Glasgow coma scale significantly improved in the magnesium group compared to milrinone group through Day 7, Day 14 and Day 21 (p = 0.036, p = 0.012, p = 0.016, respectively). The incidence of hypotension was higher with milrinone than magnesium (p = 0.012). The incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage was significantly lower and Glasgow coma scale significantly better with magnesium when compared to milrinone. Milrinone was associated with a higher incidence of hypotension and requirement for dopamine and norepinephrine when compared to magnesium." @default.
• W2899693214 created "2018-11-16" @default.
• W2899693214 creator A5033233101 @default.
• W2899693214 creator A5061393700 @default.
• W2899693214 date "2019-01-01" @default.
• W2899693214 modified "2023-09-29" @default.
• W2899693214 title "Efeitos do sulfato de magnésio e da milrinona sobre o vasoespasmo cerebral após hemorragia subaracnoidea por aneurisma: estudo randômico" @default.
• W2899693214 cites W1964294449 @default.
• W2899693214 cites W1974855968 @default.
• W2899693214 cites W1974993847 @default.
• W2899693214 cites W1977211256 @default.
• W2899693214 cites W1981212053 @default.
• W2899693214 cites W1991620304 @default.
• W2899693214 cites W1992762287 @default.
• W2899693214 cites W1993893408 @default.
• W2899693214 cites W2003009406 @default.
• W2899693214 cites W2003345747 @default.
• W2899693214 cites W2006042623 @default.
• W2899693214 cites W2007345509 @default.
• W2899693214 cites W2022912575 @default.
• W2899693214 cites W2039038247 @default.
• W2899693214 cites W2048032652 @default.
• W2899693214 cites W2056437755 @default.
• W2899693214 cites W2060752639 @default.
• W2899693214 cites W2070197010 @default.
• W2899693214 cites W2070371303 @default.
• W2899693214 cites W2080485878 @default.
• W2899693214 cites W2080665836 @default.
• W2899693214 cites W2082022147 @default.
• W2899693214 cites W2089808507 @default.
• W2899693214 cites W2090157801 @default.
• W2899693214 cites W2093460272 @default.
• W2899693214 cites W2107249030 @default.
• W2899693214 cites W2110471635 @default.
• W2899693214 cites W2139030618 @default.
• W2899693214 cites W2143790244 @default.
• W2899693214 cites W2145329794 @default.
• W2899693214 cites W2156335402 @default.
• W2899693214 cites W2163891880 @default.
• W2899693214 cites W2171516719 @default.
• W2899693214 cites W2413119590 @default.
• W2899693214 cites W2583031766 @default.
• W2899693214 doi "https://doi.org/10.1016/j.bjan.2018.09.005" @default.
• W2899693214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30409409" @default.
• W2899693214 hasPublicationYear "2019" @default.
• W2899693214 type Work @default.
• W2899693214 sameAs 2899693214 @default.
• W2899693214 citedByCount "14" @default.
• W2899693214 countsByYear W28996932142020 @default.
• W2899693214 countsByYear W28996932142021 @default.
• W2899693214 countsByYear W28996932142022 @default.
• W2899693214 countsByYear W28996932142023 @default.
• W2899693214 crossrefType "journal-article" @default.
• W2899693214 hasAuthorship W2899693214A5033233101 @default.
• W2899693214 hasAuthorship W2899693214A5061393700 @default.
• W2899693214 hasBestOaLocation W28996932141 @default.
• W2899693214 hasConcept C42219234 @default.
• W2899693214 hasConcept C71924100 @default.
• W2899693214 hasConceptScore W2899693214C42219234 @default.
• W2899693214 hasConceptScore W2899693214C71924100 @default.
• W2899693214 hasIssue "1" @default.
• W2899693214 hasLocation W28996932141 @default.
• W2899693214 hasLocation W28996932142 @default.
• W2899693214 hasOpenAccess W2899693214 @default.
• W2899693214 hasPrimaryLocation W28996932141 @default.
• W2899693214 hasRelatedWork W1506200166 @default.
• W2899693214 hasRelatedWork W1995515455 @default.
• W2899693214 hasRelatedWork W2039318446 @default.
• W2899693214 hasRelatedWork W2048182022 @default.
• W2899693214 hasRelatedWork W2080531066 @default.
• W2899693214 hasRelatedWork W2170431845 @default.
• W2899693214 hasRelatedWork W2748952813 @default.
• W2899693214 hasRelatedWork W2899084033 @default.
• W2899693214 hasRelatedWork W3032375762 @default.
• W2899693214 hasRelatedWork W3108674512 @default.
• W2899693214 hasVolume "69" @default.
• W2899693214 isParatext "false" @default.
• W2899693214 isRetracted "false" @default.
• W2899693214 magId "2899693214" @default.
• W2899693214 workType "article" @default.